What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially report and provide access to Vertex Pharmaceuticals' financial results for the third quarter of 2005, as detailed in a press release issued on October 26, 2005.

Where can I find the specific third quarter 2005 financial results?

The specific financial results for the third quarter of 2005 are located in the press release dated October 26, 2005, which is included as Exhibit 99.1 to this 8-K filing.

Does this filing contain new strategic information or forward-looking statements?

This 8-K filing primarily focuses on reporting past financial results. While the attached press release may contain some forward-looking statements, the 8-K itself is a factual reporting document of the results and does not introduce new strategic initiatives or detailed future guidance beyond what is in the press release.

What does it mean that the information is not 'filed' for Section 18 liability?

This means that while the information is publicly disclosed, Vertex Pharmaceuticals is stating that it will not be held liable under Section 18 of the Securities Exchange Act of 1934 for any potential inaccuracies in this specific Form 8-K filing, unless such information is later incorporated by reference into a registration statement or other SEC filing.

VRTX 8-K: Earnings & Results

Summary

Vertex Pharmaceuticals Incorporated filed an 8-K report on October 26, 2005, to disclose its financial results for the third quarter of 2005. This filing primarily serves to attach and incorporate by reference a press release detailing these results, providing investors with an update on the company's operational and financial performance during the period. The specific financial figures and performance metrics are contained within the referenced press release (Exhibit 99.1).

Key Highlights

1Vertex Pharmaceuticals filed a Form 8-K on October 26, 2005.
2The filing's primary purpose is to report the company's third quarter 2005 financial results.
3These results were disseminated via a press release issued on the same date.
4The press release is attached as Exhibit 99.1 to the 8-K filing.
5The information is furnished under Item 2.02 (Disclosure of Result of Operations and Financial Condition).
6The filing notes that the disclosed information is not deemed 'filed' for Section 18 liability purposes unless expressly incorporated into other filings.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Oct 26, 2005)

Summary

Key Highlights

Frequently Asked Questions